Although unknown at the time, tumour necrosis factor (TNF) first entered the world stage of cancer therapy towards the end of the 19th century when William Coley found that sarcomas shrank with certain bacterial infections 1,2 . It was not until well into the 20th century that this effect was found to be due to the induction of TNF 3 , which caused tumours to become necrotic, a feature that led to the coining of the name of the protein.
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Initial enthusiasm following the discovery of TNF was, however, dampened by the demonstration that systemic TNF treatment induced a lethal inflammatory shock syndrome 4 . In search of another molecule with similar antitumour properties, attention turned to CD95 (also known as FAS and APO-1), a receptor homologous to TNF receptor 1 (TNFR1) and TNFR2 that can potently trigger apoptosis in many cancer cells 5, 6 . However, systemic treatment with CD95 agonists led to fulminant liver toxicity in mice within hours of treatment 7, 8 , again excluding a TNF-like molecule for therapeutic use. It was third time lucky: another TNF superfamily (TNFSF) member, termed TNF-related apoptosis-inducing ligand (TRAIL; also known as TNFSF10 and APO2L), was discovered a few years later 9, 10 , and this factor was capable of killing tumour cells, importantly however, without causing the lethal adverse effects encountered with TNF or CD95 agonists 11, 12 . Although these promising findings resulted in the development of TRAIL receptor (TRAIL-R) agonists for clinical use, this happened at a time when toxicity of pro-apoptotic TNF-like factors in general, but also of TRAIL specifically 13, 14 , was a concern, as some recombinant forms of TRAIL had shown potential for liver toxicity at high doses [13] [14] [15] . Moreover, when the decision was made to take particular molecular entities forward for clinical development, the biology of TRAIL and its receptors in cancer, as well as in inflammation and immunity, was still underexplored and therefore could not adequately be taken into consideration. Since then, the situation has substantially changed. It is therefore timely to take a step back and revise our current understanding of the biology of the TRAIL-TRAIL-R system in order to move forward with novel and effective therapeutic strategies that harness this system for cancer therapy.
The TNFSF and TRAIL-TRAIL-R complexes The TNFSF. TNF is the canonical member of the TNFSF, of which TRAIL and the CD95 ligand (CD95L, also known as FASLG and APO-1L) are closely related members. Apart from lymphotoxin-α (also known as TNFSF1) and vascular endothelial growth inhibitor (also known as TNFSF15), which are encoded as soluble proteins, all other members of this family are encoded, and if not further cleaved, expressed as type II
Type II transmembrane proteins
Defined by a single transmembrane domain, an amino terminus facing the cytosol and an extracellular carboxy terminus.
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy 1 Abstract | The discovery that the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis of cancer cells without causing toxicity in mice has led to the in-depth study of pro-apoptotic TRAIL receptor (TRAIL-R) signalling and the development of biotherapeutic drug candidates that activate TRAIL-Rs. The outcome of clinical trials with these TRAIL-R agonists has, however, been disappointing so far. Recent evidence indicates that many cancers, in addition to being TRAIL resistant, use the endogenous TRAIL-TRAIL-R system to their own advantage. However, novel insight on two fronts -how resistance of cancer cells to TRAIL-based pro-apoptotic therapies might be overcome, and how the pro-tumorigenic effects of endogenous TRAIL might be countered -gives reasonable hope that the TRAIL system can be harnessed to treat cancer. In this Review we assess the status quo of our understanding of the biology of the TRAIL-TRAIL-R system -as well as the gaps therein -and discuss the opportunities and challenges in effectively targeting this pathway.
and ADAM17 (also known as TACE) have been identified to cleave CD95L and TNF, respectively, to generate their soluble forms in a process termed shedding 17, 18 . The generation of soluble TRAIL through shedding also involves cysteine protease activity 19 , but the identity of the protease (or proteases) responsible remains unknown. Soluble TRAIL is present in the plasma of a healthy adult at approximately 100 pg ml -1 (REF. 20) , a concentration at which TRAIL fails to induce apoptosis in most cell lines in vitro 21 . For CD95L, only the membrane-bound protein can induce apoptosis whereas the soluble form has cancerpromoting effects 22 . For TRAIL, this is less clear. It has, however, been shown that liposome-bound TRAIL, which mimics membrane association, is more active in killing cancer cells than its soluble counterpart 23, 24 . In this context it is conceivable that recombinant forms of TRAIL that comprise the extracellular domain fused to motifs that enable stabilization and multimerization might mimic the membrane-bound conformation. This is likely the reason why various recombinant forms that contain such motifs 11, 13, 25 are, by several orders of magnitude, more potent inducers of apoptosis than recombinant TRAIL preparations that lack such additional motifs 12 .
TNFSF members bind to a corresponding family of receptors, referred to as the TNFR superfamily (TNFRSF), which comprises more members than the TNFSF. Hence, some ligands have several receptors. Eight TNFRSF members, including TNFR1 (also known as TNFRSF1A), CD95, TRAIL-R1 (also known as DR4 and TNFRSF10A) and TRAIL-R2 (also known as DR5and TNFRSF10B) 26 contain an intracellular domain required for cell death induction, consequently referred to as the death domain (DD).
The TRAIL-TRAIL-R system. Among the members of the TNFSF, human TRAIL is unique in that it binds to four membrane receptors and one soluble receptor (FIG. 1a) . The human TRAIL-Rs can be subdivided into two classes: the full-length intracellular DD-containing receptors TRAIL-R1 (REF. 27 ) and TRAIL-R2 , which can induce apoptosis and are most widely expressed, and the alternative receptors TRAIL-R3 (also known as DCR1 and TNFRSF10C) [33] [34] [35] [36] , TRAIL-R4 (also known as DCR2 and TNFRSF10D) 37, 38 and osteoprotegerin (OPG, also known as TNFRSF11B), which also functions as a soluble receptor for receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL, also known as TNFSF11) 39 . TRAIL-R3 is anchored to the plasma membrane by glycosylphosphatidylinositol (GPI) and lacks an intracellular domain, and TRAIL-R4 contains a cytoplasmic domain that can induce NF-κB activation but not apoptosis as it encodes only a truncated DD. At 37 °C, TRAIL binds to TRAIL-R2 with higher affinity than to the other membrane-expressed TRAIL-Rs 40 . It is therefore likely that under physiological conditions, binding to TRAIL-R2 would be favoured, especially when endogenous TRAIL is limited.
All the alternative TRAIL-Rs were proposed to act as TRAIL 'decoys' , that is, their binding to TRAIL would lower the concentration of TRAIL available for binding to the pro-apoptotic receptors TRAIL-R1 and TRAIL-R2 and, thereby, negatively regulate apoptosis induction by TRAIL. Although in vitro overexpression results and additional correlative data in favour of this concept have been presented 41 , it remains to be seen whether this function is indeed exerted by any of these receptors in cancer cells under endogenous expression levels [42] [43] [44] [45] . Nature Reviews | Cancer Figure 1 | Human and mouse TRAIL-receptor systems. a | The human tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-TRAIL-receptor (TRAIL-R) system. Humans express three receptors with an intracellular domain containing a death domain (DD), or in the case of TRAIL-R4, a truncated DD. TRAIL-R2 is expressed as a long and a short isoform, which differ by the presence or absence, respectively, of a single TAPE (threonine, alanine, proline and glutamine) domain. Moreover, TRAIL-R3 is linked to the membrane via a glycosylphosphatidylinositol (GPI) anchor, expresses five TAPE domains but is devoid of an intracellular domain. Osteoprotegerin (OPG) serves as a low-affinity soluble receptor for TRAIL. b | The mouse TRAIL-TRAIL-R system. mTRAIL-R is homologous to human TRAIL-R1 and TRAIL-R2, whereas mDcTRAIL-R1 and mDcTRAIL-R2 differ significantly and the latter is also found as a soluble form. Similar to human OPG, mOPG serves as a low-affinity soluble TRAIL receptor. MPD, membrane-proximal domain.
When TNFR1 was first crystallized in complex with its ligand, it formed receptor trimers with a ligand trimer located in its core 46 . However, when not bound by its ligand, TNFR1 formed dimers 47 . Similar to TNFR1, TRAIL-Rs also exist as preassembled multimers. In the TRAIL-TRAIL-R system, however, receptor dimers are ligand induced and are present in high-molecular-weight fractions together with ligand-induced trimers 48 . Adding another level of complexity, TRAIL-R1 and TRAIL-R2 can homo-and heterotrimerize to form higher-order complexes. It has been suggested that such complexes can involve either trimer multimerization or crosslinking of neighbouring trimers via dimerization between receptor interfaces that are located opposite the ligand-binding interfaces, resulting in a hexameric honeycomb-like structure 48 . The latter model received support from two recent studies showing that non-stabilized, untagged TRAIL synergized with TRAIL-R2-specific antibodies to kill cells and that this was achieved through a ternary complex crystal structure resembling the above-mentioned honeycomb 21, 49 . The most obvious molecular difference between the two DD-containing TRAIL-Rs is that there is only one splice variant for TRAIL-R1 whereas there are two for TRAIL-R2 (REF. 50 ). The long isoform of TRAIL-R2 contains an additional 29 extracellular amino acids, which are located immediately adjacent to the membrane. As this polypeptide, rich in threonine, alanine, proline and glutamine (TAPE), also referred to as the TAPE domain 34 , is thought to form a rigid stalk as described for a highly homologous polypeptide in TNFR2 (REF. 51 ), it is likely that its presence results in protrusion of the long isoform from the glycocalyx. It is therefore tempting to speculate whether only TRAIL-Rs whose extracellular domains protrude at similar stalk-dependent heights may effectively heterotrimerize. If that were the case, TRAIL-R1, TRAIL-R4 and the short isoform of TRAIL-R2, in addition to forming homotrimers, would be capable of forming heterotrimers with each other, whereas the long isoform of TRAIL-R2 would form only homotrimers. According to this model, with five consecutive repeats of the TAPE domain 34 TRAIL-R3 would hover high above the other TRAIL-Rs and therefore also form only homotrimers.
Despite surface expression of TRAIL-R2 in cell lines derived from pancreatic cancer, chronic lymphocytic leukaemia or mantle cell lymphoma, these cells use only TRAIL-R1 for apoptosis induction by TRAIL [52] [53] [54] . In addition, apoptosis induction via TRAIL-R2 requires crosslinking of untagged soluble TRAIL 55 , implying that TRAIL-R2 might have a higher apoptotic threshold than TRAIL-R1. However, in several leukaemia and lymphoma cell lines antibody-mediated TRAIL-R2 triggering appears to be sufficient to induce apoptosis without additional crosslinking 56 . Together, these data highlight that human TRAIL-R1 and TRAIL-R2 fulfil partly overlapping but also distinct functions, many of which remain to be discerned.
In contrast to humans, mice express only a single TRAIL-R (mTRAIL-R, also known as MK) with an intracellular DD that shares almost the same level of identity with human TRAIL-R1 (43% sequence homology) and human TRAIL-R2 (49% homology); like its human counterparts, mTRAIL-R is capable of inducing apoptosis 57 . Two further mTRAIL-Rs (mDcTRAIL-R1, also known as TNFRSF23 and mDcTRAIL-R2, also known as TNFRSF22) were later described, but these lack an intracellular DD 58 (FIG. 1b) . They differ substantially in their amino acid sequence from human TRAIL-R3 and TRAIL-R4 and do not induce apoptosis or NF-κB activation upon overexpression 58 . Notably, human TRAIL binds only weakly to mTRAIL-R whereas mouse TRAIL has high affinity for the human TRAIL-Rs 59 . These findings need to be considered when designing tolerability studies in mice.
Although studies in mTRAIL-R-deficient mice have shed light on the relevance of many TRAIL-R-induced pathways in vivo, it remains unexplained why humans have evolved to express two DD-containing receptors for TRAIL. One option to study this question further would be to develop a 'humanized' mouse expressing human DD-containing TRAIL-Rs.
TRAIL-induced signalling pathways
Like other members of the TNFSF, TRAIL can trigger various biological responses in cancer and normal cells. Besides the induction of cell death by apoptosis or necroptosis (BOX 1) this includes the activation of noncell-death pathways that in turn trigger a plethora of cellular processes.
Pro-apoptotic TRAIL signalling. In 1999, two groups independently showed that systemic treatment of mice bearing xenograft tumours with recombinant forms of human TRAIL resulted in tumour regression 11, 12 . This discovery, together with the demonstration that systemic treatment with high-dose leucine zipper (LZ) Box 1 | Non-apoptotic cell death signalling by TRAIL A long-standing conundrum in cell death research was the counterintuitive finding that genetic ablation of the death-inducing signalling complex (DISC) components FAS-associated death domain (Fadd) and caspase 8 (Casp8) in mice resulted in embryonic lethality accompanied by signs of excessive cell death in embryonic tissues 164, 165 . Recently, however, it was discovered that apoptotic DISC components play an integral part in suppressing a previously unrecognized form of cell death now known as regulated necrosis or necroptosis. Necroptosis depends on the kinase activities of receptor-interacting serine/threonine protein kinase 1 (RIPK1) and RIPK3 . Importantly, embryonic lethality in Casp8 and Fadd knockout mice could be prevented by co-ablation of Ripk3 or Ripk1, demonstrating that aberrant necroptosis is responsible for prenatal death of these animals [169] [170] [171] [172] [173] . Despite an early study identifying a caspase 8-independent, RIPK1-dependent, cell death pathway induced by CD95 ligand (CD95L), tumour necrosis factor (TNF) and TNF-related apoptosis-inducing ligand (TRAIL) 166 , the field initially focused on investigating this phenomenon mainly for TNF. Much later, it was found that necroptosis triggered by CD95L and TRAIL is enabled under certain circumstances, including acidic pH 174, 175 or depletion of cellular inhibitor of apoptosis (cIAP) proteins or TNF receptor-associated factor 2 (TRAF2) [176] [177] [178] . It was further shown that necrostatin, a small-molecule inhibitor of RIPK1, can block this kind of cell death 179 . Recently, a wide variety of human cell lines have been found to undergo necroptosis upon combined treatment with TRAIL and chemotherapeutic drugs 180 . It will be interesting to explore further how induction of TRAIL-induced apoptosis versus necroptosis will affect tumour immunogenicity and how this may in turn affect tumorigenesis as well as the efficacy of cancer immunotherapy. mouse TRAIL, which was capable of killing mouse cells in vitro, was well tolerated 11 , formed the basis for the clinical development of TRAIL-R agonists. Moreover, it sparked great interest in investigating the mechanisms by which TRAIL-R1 and TRAIL-R2 initiate apoptosis, what prevents this in TRAIL-resistant cancers and how TRAIL resistance can be broken.
Upon TRAIL binding, the intracellular DDs of three ligand-crosslinked receptors adopt a conformation that enables them to recruit the intracellular adaptor molecule FAS-associated death domain protein (FADD) via its DD. FADD contains a death effector domain (DED) that enables recruitment of the initiator caspases 8 and 10 via their DEDs. The membrane-associated complex resulting from these interactions is termed the TRAIL death-inducing signalling complex (DISC) [60] [61] [62] [63] (FIG. 2) .
TRAIL DISC formation induces proximity-induced activation of caspase 8 and caspase 10, thereby further amplifying their activation through mutual cleavage. Part of the aggregation required for full caspase 8 activity can be facilitated by cullin 3-mediated nondegradative ubiquitylation of caspase 8, which leads to Nature Reviews | Cancer At this step, FLICE-like inhibitory protein (FLIP) can competitively bind to FADD and thereby limit caspase 8 recruitment. Caspase 8 is ubiquitylated by cullin 3, enhancing its clustering and activation. In cells referred to as type I, DISC formation is sufficient to trigger the full caspase cascade, resulting in apoptosis. In cells referred to as type II, full activation of caspase 3, which requires a maturation step following the initial caspase 8-mediated cleavage 185 , is inhibited by high levels of the X-linked inhibitor of apoptosis (XIAP) protein 186 . To overcome this, caspase-8 cleaves BH3-interacting domain death agonist (BID) 68 , which in its truncated form (tBID) translocates to mitochondria and activates BAX and BAK to execute mitochondrial outer membrane permeabilization (MOMP) 187 . MOMP results in the release of a natural antagonist for XIAP, second mitochondria-derived activator of caspase (SMAC), thereby relieving effector caspases from XIAP-imposed inhibition and enabling their full activation 188 . Along with SMAC, cytochrome c is released, which enables the adaptor molecule apoptotic protease activating factor 1 (APAF1) to assemble the apoptosome, an activation platform for the intracellular initiator caspase-9 (REF. 69 ). Apoptosome formation and the resulting caspase 9 activation in turn enhance caspase-3 cleavage and activity. b | Non-canonical TRAIL signalling. TRAIL can trigger the formation of a secondary cytosolic complex retaining FADD, TNF receptor-associated factor 2 (TRAF2) and nuclear NF-κB essential modifier (NEMO). Both this complex and the DISC activate nuclear factor-κB (NF-κB), p38, JUN N-terminal kinase (JNK) and ERK. Receptor-interacting serine/threonine protein kinase 1 (RIPK1) also associates with TRAIL-Rs when caspase-8 is inhibited and is required for TRAIL-induced SRC and signal transducer and activator of transcription 3 (STAT3) activation and promotion of migration. The linear ubiquitin chain assembly complex (LUBAC) is present in both complex I and complex II in TRAIL signalling where it limits caspase-8 activation and enables recruitment of the inhibitor of κB (IκB) kinase (IKK) complex, resulting in NF-κB activation 110 .
Extrinsic apoptosis
A type of apoptosis in which caspase activation is triggered by death ligands binding to cell surface death receptors.
Apoptosome
A heptameric multiprotein complex that aids caspase activation during extrinsic and intrinsic apoptosis induction following mitochondrial outer membrane permeabilization.
Microprocessor complex
A protein complex that mediates maturation of microRNAs in the nucleus.
p62 binding and aggregation of caspase 8 at the DISC 64 . Moreover, degradative K48-linked ubiquitin chains were shown to be attached to the cytosolic p18 fragment of active caspase 8 in a TNF receptor-associated factor 2 (TRAF2)-dependent manner, leading to proteasomal degradation of active caspase 8 in the cytosol, thereby serving as its shut-off timer 65 . Active caspases 8 and 10 are released into the cytosol where they cleave downstream effector caspases such as caspase 3. Importantly, albeit for reasons not entirely understood, caspase 10 cannot compensate for loss of caspase 8 despite effective recruitment to the TRAIL DISC in the absence of caspase 8 (REF. 63 ), assigning caspase 8 a central role in the initiation of extrinsic apoptosis by TRAIL.
FLICE-like inhibitory protein (FLIP, also known as CFLAR) is a caspase 8 homologue that can compete with caspase 8 for binding to FADD but does not contain catalytic activity and is consequently frequently upregu lated in cancers to mediate resistance against DISC activation and apoptosis 66, 67 . Irrespective of FLIP levels, in some cells DISC activation is insufficient to trigger extrinsic apoptosis. Here, cross-signalling to the mitochondria via cleavage of BH3-interacting domain death agonist (BID) 68 and assembly of the caspase 9-activating apoptosome 69 are essential (FIG. 2) . Apoptosome formation and the resulting caspase 9 activation in turn enhance caspase 3 cleavage and activity. Activation of effector caspases, including caspase 3, induces cleavage of a plethora of cellular proteins, ultimately resulting in the execution of apoptosis.
Non-canonical TRAIL signalling. Apart from inducing cell death, binding of TRAIL to TRAIL-R1, TRAIL-R2 and also TRAIL-R4 has been shown to induce activation of NF-κB 29, 38 , a transcription factor involved in pro-inflammatory immune responses 70 . Receptor-interacting serine/threonine protein kinase 1 (RIPK1), apart from executing necroptosis, is also involved in TRAILmediated NF-κB induction 71 by activating the inhibitor of κB (IκB) kinase complex (IKK complex), which in turn phosphorylates IκB, leading to its degradation and NF-κB nuclear translocation. Although TRAIL-induced NF-κB activation was initially suggested to simply mediate resistance to TRAIL-induced apoptosis, more recent evidence shows that NF-κB activation can serve other purposes in TRAIL-resistant cells. Accordingly, TRAIL can induce proliferation in TRAIL-resistant Jurkat cells via NF-κB as demonstrated by using RIPK1-deficient or NF-κB essential modifier (NEMO; also known as IKKγ)-deficient cells 72 . In apoptosis-resistant cholangiocarcinoma cells, TRAIL promotes NF-κB-dependent tumour cell migration and invasion without influencing proliferation 73 . In addition, RIPK1 is present in the native TRAIL DISC where it can induce NF-κB when caspases are inhibited 74 . Interestingly, these are also conditions under which necroptosis can be induced.
Furthermore, TRAIL-induced NF-κB activation is decreased in the absence of FADD and increased during co-treatment with caspase inhibitors, which is thought to be due, at least in part, to the fact that caspases cleave RIPK1, thereby rendering it unable to activate NF-κB 75 .
The anti-apoptotic protein FLIP also modulates TRAILinduced NF-κB activation, but precisely how it achieves this is still controversial. Overexpression of FLIP increases basal NF-κB activation to the same extent as caspase 8 and FADD overexpression 76 , whereas it also inhibits TRAIL-R-mediated NF-κB activation 75 . Intriguingly, the formation of a secondary intracellular signalling complex following DISC formation has been proposed to activate not only NF-κB, but also the JUN N-terminal kinase (JNK) and p38 MAPK pathways 77 . The implications of kinase pathway activation by TRAIL were recently reviewed 78 . Another member of the MAPK family, ERK, seems to be intimately involved in TRAIL-induced non-apoptotic effects 79 . TRAIL induces ERK-mediated proliferation in caspase 8-deficient small-cell lung cancer (SCLC) cells in a TRAIL-R2-dependent manner 80 . Interestingly, in certain cancer cells TRAIL-R2, which is normally expressed at the plasma membrane, was found in the nucleus, where it promotes proliferation by interacting with accessory proteins of the microprocessor complex, leading to impaired maturation of the microRNA let-7, a known negative regulator of KRAS mRNA 81 . It therefore appears that subcellular compartmentalization of TRAIL-R2 may determine distinct TRAIL-R2 signalling outputs (reviewed by Bertsch et al. 82 ). Another study demonstrated that TRAIL is expressed in highly vascularized soft tissue sarcomas and, intriguingly, soluble TRAIL induced endothelial cell migration and vessel tube formation to an extent similar to that induced by vascular endothelial growth factor (VEGF) 83 . Low-dose TRAIL was shown to trigger migration in non-small-cell lung cancer (NSCLC) cell lines in vitro in a manner dependent on RIPK1, SRC and signal transducer and activator of transcription 3 (STAT3) 84 . Moreover, oncogenic KRAS signalling rendered colorectal cancer cells resistant to TRAIL and CD95L through suppression of RHO-associated protein kinase (ROCK) activity and enabled their migration 85, 86 . Of note, the membrane-proximal domain (MPD) of TRAIL-R2, a short, ten amino-acid stretch juxtaposed to the plasma membrane, was sufficient to promote cell-autonomous RAC1 activation and migration of NSCLC cell lines with an oncogenic KRAS mutation in response to constitutive stimulation by endogenous TRAIL 86 . Interestingly, this domain is at least partially conserved between TRAIL-R2 and CD95, which can also activate RAC1 in neurons via its MPD 87 (FIG. 2) .
TRAIL and its receptors in cancer
The TRAIL-TRAIL-R system affects many physio logical and pathophysiological processes in both immunology and cancer. With respect to the immune system, TRAIL and its receptors are expressed on vari ous human innate and adaptive immune cell types. Levels of TRAIL expression on these different cells depend on the stimulation status of the immune cell. In innate immune cells, TRAIL is expressed on monocytes, macrophages, dendritic cells (DCs) and natural killer (NK) cells, after lipopolysaccharide (LPS) or pro-inflammatory cytokine stimulation, and it is involved in effector mechanisms in these cells [88] [89] [90] . Regarding adaptive immune cells, the TRAIL-TRAIL-R system has an important role in preventing aberrant T cell activation and is required for immune homeostasis in normal physi ology [91] [92] [93] [94] . Regarding cancer, depending on the type of malignancy and its particular oncogenic make-up, this system can mediate either immunosurveillance against pre-malignant cells or pro-tumorigenic effects.
Pleiotropic effects of TRAIL-TRAIL-Rs in mouse models of tumorigenesis and metastasis. One of the first indications of a role for endogenous TRAIL in regu lating tumour growth came when it was shown that Trail-deficient mice are more susceptible to transplanted mouse A20 lymphoma, as they died prematurely owing to an increased number of lymphoma nodules in the liver 95 . The influence of the TRAIL-TRAIL-R system on cancer in mouse models is summarized in TABLE 1. Moreover, administration of neutralizing antibodies against TRAIL or Trail deficiency promoted tumour development in mice treated with the chemical carcinogen methylcholanthrene (MCA) 96, 97 . The protective effect of TRAIL in this model was at least partially dependent on interferon-γ (IFNγ)-mediated upregulation of TRAIL on NK cells. TRAIL expression on NK cells is an important mechanism used by the immune system to kill cancer cells 98, 99 (FIG. 3) ; however, it cannot be excluded that TRAIL expression on other immune effector cells could also contribute to the protection against tumour development. Additional evidence for a role of TRAIL in host immune surveillance against the development of primary tumours came from studies with Trp53 +/− mice in which loss of TRAIL predisposes to development of a greater number of spontaneous tumours, including disseminated lymphomas and sarcomas 96, 100 . Trail deficiency also rendered immunocompetent mice more susceptible to experimental and spontaneous liver metastasis and tumour growth resulting from intrasplenically injected syngeneic renal carcinoma cells 95, 101 . Similarly, primary growth and spontaneous liver metastasis of syngeneic breast cancer cells injected into the mammary glands also increased in Trail-deficient mice 97 . The anti-metastatic effects observed in the spontaneous liver metastasis models could be explained mainly by the lack of TRAIL expression on hepatic NK cells as the ex vivo cytotoxicity of liver NK cells from Trail-deficient mice was dramatically reduced compared with those from control mice ;Pdx1-Cre mice; MCA, methylcholanthrene; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand; TRAIL-R, TRAIL receptor.
hepatocarcinogenesis, Trail-r deficiency promoted development of macroscopic liver lesions 102 . The same study also showed that in mice Trail-r deficiency promoted Eμ-Myc-driven lymphomagenesis as well as lung and liver metastasis as a result of loss of mTRAIL-R-mediated cell death in lymphomas. In addition, mTRAIL-R acts as a specific suppressor of metastases in an autochthonous model of skin carcinogenesis. In this model, metastasis suppression occurred without affecting primary epithelial skin tumorigenesis and was due to TRAIL sensitization Nature Reviews | Cancer of detached cancer cells 103 . As TRAIL expression on NK cells contributes to immune surveillance, it seems likely that TRAIL-expressing NK cells could be the effector cells responsible for the death of detached skin carcinoma cells via TRAIL-R-mediated apoptosis 104 .
In contrast, cancer cell-expressed endogenous mTRAIL-R was shown to promote progression, invasion and metastasis of autochthonous Kras-driven pancreatic and lung cancer in a cell-autonomous manner via activation of RAC 86 . In contrast to previous studies, cancer cell-restricted deletion of mTRAIL-R in the presence of intact TRAIL-mTRAIL-R signalling in all other cells was studied here for the first time. It is, therefore, possible that intact TRAIL-mTRAIL-R signalling in non-tumour cells contributes to overall cancer promotion. In line with this notion, it is interesting that shorter survival of tumour-supportive myeloid-derived suppressor cells (MDSCs) and tumour-associated macrophages (TAMs), referred to as type 2 myeloid cells, is caused by caspase 8-dependent apoptosis via TRAIL-R2 (REFS 105,106). These data suggest that at least some of the effects seen in cancer models studying whole-body Trail-r-deficient mice could be due to increased numbers of MDSCs and, thereby, immune regulation and tumour promotion rather than just the absence of TRAILinduced apoptosis in cancer cells. In addition, activation of TRAIL-R on tumour endothelial cells was shown to induce their apoptosis, causing vascular disruption with consequent reduction in tumour growth in a genetically engineered mouse model of pancreatic cancer 107 . Interestingly, TRAIL-induced stimulation of TRAIL-Rs on cancer cells has also recently been shown to induce the secretion of cytokines, most importantly C-C motif chemokine ligand 2 (CCL2), resulting in recruitment of tumour-supporting type 2 myeloid cells that express chemokine (C-C motif) receptor 2 (CCR2), thereby contributing to tumour growth 108 . Of note, unlike RAC1 activation, induction of the TRAILinduced cancer secretome requires FADD and the scaffold function of caspase 8 but not its enzymatic activity, implying that cancer cell-expressed TRAIL-Rs can trigger distinct but parallel signalling pathways to promote cancer 108, 109 . Interestingly, the linear ubiquitin chain assembly complex (LUBAC) was recently identified to regulate TRAIL-induced gene activation and cell death and to be required for TRAIL-induced cytokine production downstream of FADD, caspase 8, cellular inhibitor of apoptosis 1 (cIAP1) and cIAP2 (REF. 110 ).
The results from these experimental mouse models of cancer highlight that the role of the TRAIL-TRAIL-R system in cancer biology is diverse and can only be fully understood through cell-population-specific deletion, an undertaking that is far from complete and therefore an area of research that deserves further attention. Importantly, as mentioned above, mTRAIL-R is homologous to both human TRAIL-R1 and human TRAIL-R2, also highlighting that not all aspects of human TRAIL-R biology can be studied in the mouse system. Therefore, the development of a mouse expressing a 'humanized' TRAIL-TRAIL-R system could also be an interesting approach to further dissect the pro-and antitumour signalling pathways triggered by human TRAIL-R1 as compared with TRAIL-R2.
Clinical trials of TRAIL-R agonists
As noted above, TRAIL's ability to induce apoptosis selectively in cancer cells 11, 12 led to the clinical development of several agonists for TRAIL-Rs. They fall into two categories: recombinant forms of TRAIL and agonistic antibodies against TRAIL-R1 and TRAIL-R2 (current clinical trials using TRAIL-R agonists are summarized in TABLE 2) . However, to date none of these agonists has produced a clinical benefit in cancer patients 111 . It appears that there are three main contributors to the failure of clinical trials conducted so far with TRAIL-R agonists: insufficient agonistic activity of the drug candidate in question, resistance of many primary cancer cells to monotherapy with TRAIL-R agonists 49, 112 and lack of suitable biomarkers to identify patients who are more -or less -likely to respond to a particular TRAIL-R agonist-comprising therapy 113 .
Recombinant forms of TRAIL. Several recombinant TRAIL formulations have been developed with the aim of increasing stability and/or tumour-specific delivery of TRAIL. Stabilization of the TRAIL trimer has been attempted by the addition of N-terminal tags such as poly-histidine 10 , FLAG epitope 9 , LZ 11 and isoleucine 
Anti-drug antibody (ADA) response
An adverse immune response to a therapeutic protein that can interfere with the drug pharmacokinetics, pharmacodynamics, safety and efficacy.
zipper (IZ) motifs 13 , the fusion of TRAIL to the Fc portion of human immunoglobulin G (IgG) 114 and fusion of TRAIL to human serum albumin 115 . To increase the tumour delivery of TRAIL and, concomitantly, reduce TRAIL dilution in circulation, two main drug delivery approaches have been followed: passive targeting based on coupling TRAIL to nanoparticles and active targeting via antibody fragments or peptides that specifically target cancer cells or components of the tumour microenvironment (reviewed by de Miguel et al.
116
). The only recombinant form of TRAIL developed to date for clinical application is the non-tagged APO2L.0 (also known as dulanermin and AMG-951), which comprises amino acids 114-281 of the extracellular domain of human TRAIL 12 . Dulanermin, as opposed to receptor-specific antibodies, has the advantage of targeting both TRAIL-R1 and TRAIL-R2, rendering it less dependent on expression of only one of them. However, despite encouraging preclinical results with this protein 12, 13, 15, 117 , clinical trials failed to show any significant anticancer activity 111,118,119 . Two particular characteristics of dulanermin are most likely the main culprits for this failure: its reported short half-life of approximately 30 minutes in vivo 117,120 and its weak capacity to induce higher-order clustering of TRAIL-Rs 21, 49 , which we will revisit in detail later. In addition, any recombinant form of TRAIL, including dulanermin, may also engage the non-apoptosis-inducing TRAIL-Rs (TRAIL-R3, TRAIL-R4 and OPG). Despite the fact that the putative decoy function of these receptors in cancer cells remains to be demonstrated in non-overexpression systems 41 , it is likely that in cancers in which the ratio of non-celldeath-inducing TRAIL-Rs to death-inducing TRAIL-Rs is particularly high, the apoptosis-inducing capacity of any recombinant form of TRAIL would be lessened.
Agonistic TRAIL-R-specific antibodies. Antibodies developed as specific TRAIL-R1 or TRAIL-R2 agonists are more stable and have substantially longer half-lives than dulanermin. However, despite encouraging anti cancer activity achieved in preclinical models, TRAIL-R1-and TRAIL-R2-specific antibodies neither improved objective response rates nor increased overall patient survival [121] [122] [123] [124] [125] [126] . The clinical failure of antibodies as death receptor agonists might, however, be explained by their bivalent mode of receptor binding; in the early 1990s it was shown in the context of the death receptor CD95 that non-crosslinked bivalent antibodies against CD95 are insufficient to induce apoptosis as, at the very least, trimerization of the receptor is required, as discussed above 127 . Although TRAIL-R2-agonistic antibodies can trigger DISC formation, this is enhanced by crosslinking 128 , highlighting that higher-order complex formation is still needed for high levels of apoptosis induction.
Consequently, novel TRAIL-R agonists have been designed with the aim of rendering them more potent in activating the apoptosis-inducing capacity of TRAIL-R1 and/or TRAIL-R2 (REF. 129 ). Among them, TAS266 was first to reach the clinic. TAS266 is a novel agonistic tetravalent nanobody targeting TRAIL-R2, consisting of four identical humanized high-affinity heavy chain domain (VHH) antibody fragments, occurring naturally in camelid species, connected through three linkers of 35 amino acids each 130 . As each VHH domain can bind to TRAIL-R2 with high affinity, TAS266 has the potential to cluster four TRAIL-R2 molecules simultaneously, leading to efficient DISC formation and apoptosis induction 131 . However, when a phase I clinical study in patients with advanced solid tumours was initiated to evaluate the safety and tolerability of TAS266, the trial unfortunately had to be terminated early owing to the rapid elevation of liver enzyme levels, indicative of acute toxicity in three patients 130 . Although not investigated in depth, the acute but reversible toxicity likely stemmed from the fact that these patients had pre-existing anti-camelid antibodies binding to TAS266 and thereby suffered from an antidrug antibody (ADA) response which apparently increased the agonistic activity of TAS266 (REF. 130 ).
Of note, administering dulanermin to cynomolgus monkeys induced the production of ADAs. These ADAs were directed against the only four amino acids in which human and cynomolgus monkey TRAIL differ and were shown to be responsible for the observed liver toxicity 132 . This striking result emphasizes the importance of considering the immunogenic potential of a novel biotherapeutic agent, especially when it is designed to act as an agonist. Specifically for TRAIL-R agonists, the results with TAS266 in humans and dulanermin in cynomolgus monkeys also imply that the desirable level of activity is probably not the highest possible, but an intermediate one that perhaps best mimics the activity exerted by cell surface-expressed TRAIL. Therefore, the clinical success of a novel TRAIL-R agonist will likely depend on the right mixture of increased agonistic activity and a suitable safety profile. Consequently, when designing novel TRAIL-R agonists, apart from optimizing their agonistic activity, it will be important to minimize possible adverse effects; potential immunogenicity is a crucial factor to consider. It will be interesting to see whether the two TRAIL-R agonists that are most advanced in preclinical development 25, 133 fulfil these requirements once they are tested in humans.
Combination of TRAIL-R agonists. As TRAIL-R binding of a supposedly agonistic TRAIL-R-specific antibody might interfere with the interaction between endogenous TRAIL and its receptors, treatment with such antibodies might even be counterproductive by preventing the killing of cancer cells by endogenous TRAIL. Surprisingly, soluble untagged TRAIL in the form of dulanermin and the agonistic TRAIL-R2-specific antibody AMG-655, both of which exhibit only limited single-agent activity in killing cancer cells, synergized in the killing of cancer cells 21, 49 . This result was due to a concomitant binding of TRAIL and AMG-655 to TRAIL-R2 via distinct epitopes, which led to enhanced multimerization of TRAIL-R2 and, consequently, increased formation of the TRAIL DISC. Recently, the mere stabilization of higher-order DISCs was shown to be sufficient to sensitize cancer cells, but importantly not primary hepatocytes, to TRAIL-induced apoptosis 21, 49 . Intriguingly, together they were about as active as an IZ-tagged stabilized trimeric form of recombinant TRAIL. Importantly, both dulanermin and AMG-655 have been used in several clinical trials, either alone or combined with other drugs, without causing acute adverse effects, including no ADA response. Their combined clinical application should therefore be feasible, offering the possibility of a clinical trial testing their efficacy in combination.
Resistance and biomarkers. Although TRAIL can specifically kill many cancer cells, it is now well established that most primary cancers are resistant to TRAIL-R agonist monotherapy. Primary epithelial cancer cells isolated from colon, breast and lung carcinomas, as well as primary olfactory neuroblastoma and leukaemia cells are TRAIL resistant 72, 112, 134 . Furthermore, most primary high-grade serous ovarian cancer cells derived from ascites of patients with chemotherapy-resistant disease are also resistant to TRAIL-induced apoptosis 21, 49, [135] [136] [137] . The identification and drug-mediated removal of factors causative of this resistance are crucial to sensitize cancer cells to TRAIL-induced apoptosis (previously reviewed in REFS 111, 116, 138) . Interestingly, resistance to TRAIL can also arise through cell-to-cell variability in initial TRAIL sensitivity within clonal cell populations 139
. To date, many TRAIL-sensitizing strategies have been tested, such as the combination of TRAIL-R agonists with proteasome inhibitors (reviewed by de Wilt et al. 140 ), standard chemotherapeutic agents, second mitochondria-derived activator of caspase (SMAC) (also known as DIABLO) mimetics, BH3 mimetics to antagonize anti-apoptotic BCL-2 family members, or various kinase inhibitors (for example, those that inhibit AKT or PI3K) (previously reviewed in REFS 111,113). However, many of these studies show only limited therapeutic activity in vivo and likely also underestimate potential in vivo toxicity 99 . Recently, inhibition of cyclin-dependent kinase 9 (CDK9) was described as the most potent TRAIL sensitization strategy discovered to date. CDK9-inhibitory drugs, of which several are currently in clinical development, exquisitely sensitize NSCLC cell lines to TRAIL-induced apoptosis via the concomitant downregulation of two anti-apoptotic factors, MCL1 and FLIP, thereby simultaneously increasing DISC-generated caspase 8 activity and removing a mitochondrial block to maximal apoptosis induction 141 . As a result, the combination of IZ-TRAIL with the CDK9 inhibitor SNS-032 rendered many TRAIL-resistant cancer cells highly TRAIL sensitive, whereas the sensitization of primary human hepatocytes was more limited 141 . Thus, success of future combination therapies comprising an optimized TRAIL-R agonist will depend not only on simultan eous neutralization of various factors that together cause TRAIL resistance but also on the cancer cell selectivity of the apoptosis sensitization.
The identification of valid biomarkers that will predict which patients will benefit from TRAIL-based therapy is also an important aspect to consider when using TRAIL-R agonists. At present, the expression of TRAIL-R1 and/or TRAIL-R2 serves as the only marker to identify patients who are likely to benefit from therapy comprising a TRAIL-R agonist. High expression of the O-glycosyltransferase GALNT14 was proposed to be a signature of TRAIL sensitivity 142 . However, GALNT14-positive patients had only a trend towards increased progression-free survival and overall survival, and there was no significant correlation between tumour GALNT14 expression and clinical response to dulanermin in a randomized phase II study of patients with advanced NSCLC
119
. However, this may not be the same for more potent TRAIL-R agonists. In summary, the task of identifying a useful marker or marker set for deciding which patients may benefit from therapy that includes a TRAIL-R agonist is far from complete. Approaches involving the use of high-throughput screening of large cell line collections with known mutations 143 may turn out to be useful for the identification of such markers.
In the context of biomarkers it should also be noted that high expression of TRAIL-R2 correlated with parameters of malignancy in patients with KRASmutated colorectal or pancreatic cancer 86 and high TRAIL expression correlated with higher probability of Cancer cells have developed various mechanisms of resistance that operate at different points along the extrinsic apoptosis pathway. For example, upregulation of FLICE-like inhibitory protein (FLIP) blocks apoptosis at the death-inducing signalling complex (DISC), upregulation of anti-apoptotic BCL-2 family members blocks apoptosis at the mitochondria; there are many more, and these have been extensively reviewed elsewhere 111,113,138,181 so will not be reiterated here. More recently, however, a cell population-based approach has demonstrated that cell-to-cell variability in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance in clonal cell populations is caused by varying levels of BCL-2 family protein expression at any one time 139 . This model suggests that emerging TRAIL resistance upon persistent TRAIL exposure might be a consequence of selection of pre-existing cells expressing high levels of BCL-2 protein rather than the actual upregulation of these anti-apoptotic proteins. This concept also suggests that the frequently encountered TRAIL resistance of primary cancer cells 112 might have been caused by previous exposure to selection via the extrinsic apoptosis pathway. Interestingly, inactivating caspase 8 (CASP8) mutations are frequently found in biopsy samples from various solid tumour entities suggesting that this might be a key strategy of tumours to escape extrinsic apoptosis induced by cytolytic immune infiltrates 182 . Moreover, epigenetic silencing of CASP8 is a frequent event in small-cell lung cancer (SCLC) 183 , again suggesting that selective pressure via the extrinsic apoptosis pathway might be responsible for TRAIL resistance of these cells 80 . Thus, studying TRAIL resistance arising during clonal evolution within cancer cell populations will likely uncover both naturally occurring selection mechanisms within tumours and novel therapeutic options that might eliminate pre-existing resistant clones and, consequently, the resistance driven by them.
developing metastases in patients with KRAS-mutated NSCLC 144 . Therefore, KRAS mutation should be considered an exclusion criterion for stand-alone treatment with a TRAIL-R agonist. Importantly, in KRAS-mutated cancer the TRAIL-TRAIL-R system can promote progression, invasion and metastasis, suggesting that in these cancers the pro-tumorigenic function of TRAIL-R signalling might be positively selected for 86 . Thus, for patients with KRAS-mutated cancers, the inhibition of TRAIL or TRAIL-R2 should be explored as a therapeutic approach instead.
Apoptosis-inducing therapies harnessing the endo genous TRAIL-TRAIL-R system. Apart from the strategies discussed above of activating TRAIL-Rs on cancer cells through agonists with improved activity or, alternatively, blocking them in the context of KRAS-mutated cancers, another therapeutic strategy might be to make use of the fact that several US Food and Drug Administration (FDA)-approved drugs and newer therapeutics in advanced clinical trials have been shown to activate caspase 8, suggesting activation of a TNFRSF death receptor pathway. Interestingly, the cyclooxygenase 2 (COX2, also known as PTGS2) inhibitor celecoxib has been shown to induce TRAIL-R2-dependent caspase 8 activation and apoptosis in NSCLC cell lines 145 . It is therefore not surprising that celecoxib treatment also sensitized malignant glioma and hepatocellular carcinoma cell lines to apoptosis induced by exogenously added TRAIL 146, 147 . Of note, celecoxib-mediated sensitization of lymphoma cells to TRAIL-induced apoptosis was subsequently shown to be independent of COX2 inhibition 148 . Treatment of leukaemia cells with all-trans-retinoic acid (ATRA) upregulated TRAIL expression, which contributed to apoptosis induction by ATRA 149 . In addition, the antitumour activity of trabectedin, a DNA-binding molecule produced by the sea squirt, partially involved killing of TAMs through TRAIL-mediated caspase 8 activation 106 . More recently, the endoplasmic reticulum (ER) stress-inducing agents thapsigargin and brefeldin-A were shown to converge on TRAIL-R2 during ER stress to induce caspase 8-dependent cell death 150 .
Nature Reviews | Cancer Moreover, the small molecule ONC201 (also known as TIC10) was identified to induce TRAIL gene expression, and had potent antitumour cell activity in vitro 151, 152 . These findings, together with the fact that many cancers highly express endogenous TRAIL-Rs, suggest that one strategy to harness the TRAIL-TRAIL-R system for therapy might be through sensitization to endogenous TRAIL-R-mediated apoptosis. This strategy would also enable the expression of TRAIL, its apoptosis-inducing receptors and perhaps some key pro-apoptotic factors involved in TRAIL-induced apoptosis, such as FADD and caspase 8, potentially to be used as clinical markers for patient selection.
The TRAIL-TRAIL-R system in cancer immunotherapy: to block or to activate? It is now well established that the immune system is crucial for both tumour progression and treatment response 153 . Blockade of the immune checkpoint molecules cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and/or programmed cell death protein 1 (PD1)-PD1 ligand 1 (PDL1) has shown striking therapeutic efficacy in patients with advanced melanoma and now also several other cancers, including NSCLC 154 . However, in a substantial proportion of patients with these cancers, and certainly in several other cancer entities, the therapeutic effect of immune checkpoint blockade is more limited. Although conventional or targeted anticancer therapies mostly act by killing cancer cells, many of these therapies also affect the immune system, which will potentially contribute to their therapeutic efficacy. In a recent study, it was shown that COX1 and COX2 inhibition enhanced the efficacy of a PD1-blocking antibody, suggesting that production of immunosuppressive factors by the tumour is a potent additional mechanism of tumour immune escape 155 . As celecoxib induces tumour cell apoptosis through TRAIL-R2 as discussed above 145 , it would be interesting to investigate whether the TRAIL-TRAIL-R system contributes to, or synergizes with, the combination therapy of COX inhibition with PD1 blockade.
Several studies have shown that TAMs express TRAIL-Rs, suggesting that TRAIL-Rs could be potential targets for selectively eliminating these cells 105, 106 . Moreover, TRAIL was recently shown to significantly reduce the number of intratumoural regulatory T cells (T reg cells) 156 by promoting their apoptosis, and T reg cell depletion has proved an effective therapeutic strategy to elicit antitumour immunity in a wide variety of mouse models of cancer [157] [158] [159] [160] [161] . Therefore, and as the TRAIL-TRAIL-R system can induce the killing not just of cancer cells but also of tumour-supportive immune cells, TRAIL-R agonists could perhaps be combined with immunotherapy for the treatment of certain cancers (FIG. 3) .
TRAIL has, however, also been shown to promote an immunosuppressive cancer microenvironment, to induce proliferation of T reg cells and to act as one of the mechanisms by which T reg cells suppress effector immune cells 92, 93, 162 . TRAIL can also contribute to a T cell-suppressing microenvironment by inducing pro-inflammatory cytokines that enable myeloid cell polarization towards MDSC and fully differentiated alternatively activated (M2) macrophage phenotypes 108, 163 . Therefore, in certain cancers, antagonizing endogenous TRAIL-TRAIL-R signalling might exert a beneficial effect not just through suppression of cancer cell-autonomous promotion of cancer 86 but also by interfering with T reg and type 2 myeloid cell activity. Hence, TRAIL-TRAIL-R blockade might be an alternative, perhaps additional, therapeutic strategy to consider in the context of immune checkpoint inhibition (FIG. 3) .
Clearly, the previous two paragraphs provide rather divergent, indeed opposing, principles for future development. Yet, it is entirely possible that certain cancer patients will benefit from therapies comprising a TRAIL-R agonist whereas for others a TRAIL antagonist-comprising therapy may prove more suitable. It is therefore crucial to uncover the underlying biological principles and mechanisms that determine whether a cancer patient is likely to benefit from one versus the other therapeutic concept and to identify biomarkers that can guide such therapeutic decisions.
Conclusions and perspective
On the basis of the results obtained to date and the above discussion, we propose four therapeutic concepts harnessing different systemic functions of the TRAIL-TRAIL-R system in a cancer context-dependent manner (FIG. 4) . First, developing and using optimized multimeric variants of TRAIL or other TRAIL-R1 or TRAIL-R2 agonists in combination with potent sensitizers to TRAIL-induced apoptosis to overcome cancer cell resistance to current TRAIL-based therapeutic approaches. Second, using FDA-approved drugs that can induce tumour cell death via engagement of the endogenous TRAIL-TRAIL-R system. Third, blocking TRAIL-TRAIL-R systemically to neutralize both its autocrine and its paracrine tumour-supportive roles in KRAS-mutated cancers. Finally, combining any of these three concepts with immune checkpoint blockade could prove efficacious. Determining which patients will benefit most from each of these strategies and deciphering the underlying biology thereof will be the crucial feats of the future.
